Parkinson's Disease Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, FAScinate The

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parkinson's Disease pipeline constitutes 140+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Parkinson's Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market.

The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get more detailed insights, at:
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Some of the key takeaways from the Parkinson's Disease Pipeline Report:
• Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years.
• Parkinson's Disease companies working in the treatment market are Neuropore Therapies, Inc., Aspen Neuroscience, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Denali Therapeutics, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment
• Emerging Parkinson's Disease therapies in the different phases of clinical trials are- NPT1220-478, ANPD002, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, KM-819, Prasinezumab, P2B001, DNL 151, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years.
• In January 2023, The development of a new strategic partnership between Neurocrine Biosciences and Voyager Therapeutics to advance many gene therapies for the treatment of neurological illnesses was announced. A GBA1 gene replacement payload and novel capsids from Voyager's TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform are combined in the preclinical, intravenously administered GBA1 gene therapy programme for Parkinson's and other GBA1-mediated diseases. Additionally, Voyager and Neurocrine Biosciences have decided to work together on three new gene therapy projects that target uncommon CNS targets and each make use of Voyager's cutting-edge TRACER capsids.
• In October 2022, Approximately 400 people with Parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 (LRRK2) gene will participate in the global Phase 3 LIGHTHOUSE study to compare the efficacy and safety profile of BIIB122 (DNL151) to placebo. This study is sponsored by Biogen Inc. and Denali Therapeutics Inc.
• In September 2022, The two companies established a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease, which is a precision drug for genetically determined neurological and immunological illnesses. Neuron23 is an early-stage biotechnology business.
• In February 2021, A 58-week open-label trial of tavapadon for Parkinson's disease was started by Cerevel Therapeutics. This study's objective is to assess the efficacy and safety of providing Parkinson's disease patients with flexible tavapadon doses over an extended period of time. During the 58-week treatment term, participants will receive one Tavapadon tablet orally at a dose of 5 mg to 15 mg.

Parkinson's Disease Overview
Parkinson's disease (PD) is a neurodegenerative condition that primarily affects dopamine-producing ("dopaminergic")neurons in the substantia nigra, a particular region of the brain.

Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include:
• NPT1220-478: Neuropore Therapies, Inc.
• ANPD002: Aspen Neuroscience
• UCB7853: UCB Biopharma
• UB-312: Vaxxinity
• Emrusolmin: Modag
• PT320: Peptron
• KDT-3594: Kissei Pharmaceutical
• KM-819: FAScinate Therapeutics
• Prasinezumab: Hoffmann-La Roche
• P2B001: Pharma Two B Ltd.
• DNL 151: Denali Therapeutics
• Tavapadon: Cerevel Therapeutics

Parkinson's Disease Route of Administration
Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Parkinson's Disease Molecule Type
Parkinson's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Parkinson's Disease Pipeline Therapeutics Assessment
• Parkinson's Disease Assessment by Product Type
• Parkinson's Disease By Stage and Product Type
• Parkinson's Disease Assessment by Route of Administration
• Parkinson's Disease By Stage and Route of Administration
• Parkinson's Disease Assessment by Molecule Type
• Parkinson's Disease by Stage and Molecule Type

DelveInsight's Parkinson's Disease Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies at:
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Parkinson's Disease Therapeutics Market include:
Key companies developing therapies for Parkinson's Disease are - Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.

Parkinson's Disease Pipeline Analysis:
The Parkinson's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment.
• Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies-
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Pipeline Market Drivers
• Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market.

Parkinson's Disease Pipeline Market Barriers
• However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth.

Scope of Parkinson's Disease Pipeline Drug Insight
• Coverage: Global
• Key Parkinson's Disease Companies: Neuropore Therapies, Inc., Aspen Neuroscience, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Denali Therapeutics, Cerevel Therapeutics, and others
• Key Parkinson's Disease Therapies: NPT1220-478, ANPD002, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, KM-819, Prasinezumab, P2B001, DNL 151, Tavapadon, and others
• Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies
• Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers

Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Report Introduction
2. Parkinson's Disease Executive Summary
3. Parkinson's Disease Overview
4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Pipeline Therapeutics
6. Parkinson's Disease Late Stage Products (Phase II/III)
7. Parkinson's Disease Mid Stage Products (Phase II)
8. Parkinson's Disease Early Stage Products (Phase I)
9. Parkinson's Disease Preclinical Stage Products
10. Parkinson's Disease Therapeutics Assessment
11. Parkinson's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson's Disease Key Companies
14. Parkinson's Disease Key Products
15. Parkinson's Disease Unmet Needs
16 . Parkinson's Disease Market Drivers and Barriers
17. Parkinson's Disease Future Perspectives and Conclusion
18. Parkinson's Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
Parkinson's Disease Market https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Parkinson's Disease Epidemiology https://www.delveinsight.com/report-store/parkinsons-disease-epidemiology-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.